NGEN
Nervgen Pharma Corp
NASDAQ · Pharmaceuticals
$3.88
+0.05 (+1.31%)
Open$3.89
Previous Close$3.83
Day High$4.03
Day Low$3.84
52W High$8.49
52W Low$2.57
Volume—
Avg Volume125.6K
Market Cap418.66M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+221.9% upside
Current
$3.88
$3.88
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,058.18 | +3.66% | 48.5 | 1.00T |
| JNJ | Johnson & Johnson | $239.99 | +0.93% | 21.6 | 578.21B |
| MRK | Merck & Co. Inc. | $121.93 | +1.82% | 16.6 | 302.63B |
| PFE | Pfizer Inc. | $27.22 | +2.76% | 19.9 | 154.76B |
| BMY | Bristol-Myers Squibb Co | $61.99 | +4.15% | 17.9 | 126.20B |
| ZTS | Zoetis Inc | $127.42 | +0.54% | 21.5 | 56.95B |